The global Age-Related Vision Dysfunction Market is set for steady expansion, projected to grow from USD 96.8 billion in 2025 to USD 139.2 billion by 2035, according to a new report from Future Market Insights. The industry is forecast to record a compound annual growth rate (CAGR) of 3.7%, propelled by an aging global population, increasing awareness of vision health, and rapid technological innovation in ophthalmic diagnostics and therapeutics.
Industry Trends Driving Growth
The burden of cataracts, glaucoma, presbyopia, and age-related macular degeneration (AMD) is rising with extended life expectancy worldwide. Cataracts alone are projected to capture 35.0% of the market in 2025, making it the leading dysfunction segment due to widespread prevalence and advances in surgical solutions such as intraocular lenses.
Pharmacological interventions are also witnessing strong uptake. Eylea is projected to hold 22.5% of market share in 2025, cementing its role as a frontline therapy for retinal disorders. Expanded indications and favorable clinical performance have made Eylea a cornerstone in the pharmacologic management of vision dysfunction.
Click Here for More Information:- https://www.futuremarketinsights.com/reports/age-related-vision-dysfunction-market
Key market drivers include:
- Demographic Shifts – A growing geriatric population is accelerating demand for early detection and treatment.
- Technological Innovations – From nanotechnology-based diagnostics to robotic-assisted eye surgery, cutting-edge solutions are reshaping patient care.
- Awareness Campaigns – Global initiatives such as WHO’s VISION 2024 and World Sight Day are enhancing patient education and preventive eye care adoption.
Regional Outlook
- North America is forecast to maintain a dominant share with a CAGR of 3.6%, driven by high healthcare spending, awareness campaigns, and the rising incidence of diabetes-related vision impairment. The U.S. is projected to hold 33.8% of the regional market by 2035.
- Asia-Pacific will emerge as a growth hotspot with a projected CAGR of 3.5%. China leads the region with a rapidly aging population, advanced medical technologies, and government-supported eye health programs. India, projected at a 3% CAGR, presents opportunities as urbanization and screen use fuel demand for vision care solutions.
- Europe continues to adopt proactive screening programs and advanced therapeutics, supporting steady demand across Germany, the UK, France, and Italy.
Competitive Landscape and Recent Developments
The market is moderately consolidated with leading players including Novartis, AbbVie, Santen Pharmaceutical, Aerie Pharmaceuticals, Sun Pharma Advanced Research Company Limited, Bausch + Lomb, Eyenovia, Orasis Pharmaceuticals, and IVERIC Bio.
Recent strategic moves include:
- AbbVie strengthening its ophthalmology pipeline with the acquisition of Allergan plc in 2024, enhancing its leadership in age-related vision dysfunction therapies.
- Santen Pharmaceutical’s launch of DIQUAS® Ophthalmic Solution 3% in Japan (November 2025), designed to stimulate tear production and address dry eye conditions.
- Bausch + Lomb securing FDA clearance (December 2025) for its preservative-free Biotrue Hydration Boost Contact Lens Rehydrating Drops, expanding its eye health portfolio.
Emerging start-ups are also innovating aggressively. Nanodropper, Inc. developed a cost-saving eyedrop converter to minimize waste, while Visus Therapeutics is advancing novel formulations for presbyopia, reflecting growing opportunities in niche segments.
Challenges to Market Growth
Despite strong momentum, high drug pricing remains a key challenge, particularly for gene therapies and advanced biologics. Accessibility and affordability continue to be critical factors in ensuring widespread adoption, especially in emerging markets.
Industry Benchmarks and Future Outlook
Compared to a modest CAGR of 2% between 2020–2025, the 2025–2035 forecast period shows stronger acceleration at 3.7%. This growth trajectory is in line with rising healthcare investments and a surge in preventive ophthalmology initiatives worldwide.
The increasing integration of artificial intelligence in diagnostics, nanotechnology in drug delivery, and robotic-assisted surgical precision are expected to be major differentiators for companies seeking competitive advantage. As patient-centric models and early screening programs gain traction, the market is set to evolve toward preventive and personalized ophthalmic care.
Get Sample Report: – https://www.futuremarketinsights.com/reports/sample/rep-gb-16212
Key Market Highlights
- Market Value 2025: USD 96.8 Billion
- Market Value 2035: USD 139.2 Billion
- CAGR (2025–2035): 3.7%
- Leading Dysfunction Segment (2025): Cataract – 35.0%
- Leading Drug (2025): Eylea – 22.5%
- Key Growth Regions: North America, Asia-Pacific, Europe
- Top Players: Novartis, AbbVie, Bausch + Lomb, Santen Pharmaceutical, Aerie Pharmaceuticals
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
